Evaluation of mesenchymal stem cell migration after equine tendonitis therapy.
Authors: Carvalho A M, Yamada A L M, Golim M A, Álvarez L E C, Hussni C A, Alves A L G
Journal: Equine veterinary journal
Summary
# Editorial Summary Mesenchymal stem cell (MSC) therapy shows promise for equine tendonitis, yet uncertainty persists regarding cell behaviour and migration patterns after implantation. Carvalho and colleagues used nanocrystal labelling to track adipose-derived MSCs in four horses with induced superficial digital flexor tendon (SDFT) lesions in both forelimbs, implanting labelled cells into only one limb and subsequently monitoring peripheral blood and contralateral tendon biopsies via flow cytometry and fluorescence microscopy. Whilst labelled cells successfully entered the bloodstream in all animals, they remained localised to the treated tendon and did not migrate to the contralateral untreated lesion, suggesting MSCs do not spontaneously migrate systemically to remote tendon injuries. This finding has important implications for treatment planning: practitioners should expect intralesional MSC implantation to act primarily at the injection site rather than as a systemic therapy, meaning bilateral tendon injuries would require separate treatment protocols rather than relying on cell migration to address contralateral lesions.
Read the full abstract on PubMed
Practical Takeaways
- •MSC therapy appears to work locally at the implantation site rather than through systemic distribution to other lesions, suggesting bilateral lesions may require bilateral treatment
- •Nanocrystal tracking technology can be used to monitor MSC behaviour and guide future stem cell therapy protocols in clinical practice
- •The absence of migration to contralateral lesions indicates MSCs rely on local factors at the implantation site and do not spontaneously migrate to other damaged tendons
Key Findings
- •Labelled adipose-derived MSCs were detected in peripheral blood of all 4 horses after intralesional implantation
- •Labelled cells were identified only in treated SDFT lesions, not in contralateral untreated tendons
- •Nanocrystal labelling proved effective for in vivo tracking of MSCs in tendon tissue
- •MSCs migrate to the bloodstream but do not appear to home to untreated distant tendon lesions